Skip to main content
Top
Published in: Digestive Diseases and Sciences 9/2006

01-09-2006 | Original Paper

Prevalence of Septic Events, Type 1 Hepatorenal Syndrome, and Mortality in Severe Alcoholic Hepatitis and Utility of Discriminant Function and MELD Score in Predicting These Adverse Events

Authors: Sumita Verma, Ketan Ajudia, Michel Mendler, Allan Redeker

Published in: Digestive Diseases and Sciences | Issue 9/2006

Login to get access

Abstract

We sought to assess prevalence, and utility of discriminant function (DF) and MELD score in predicting septic events (SE), type 1 hepatorenal syndrome (HRS), and short-term mortality in severe alcoholic hepatitis (AH). Charts of patients with AH (group 1) and cirrhosis without AH (group 2) were retrospectively reviewed. Severe AH, discriminant function (DF) ≥ 32 was treated with pentoxifylline. One hundred ninety-five patients were enrolled in the study and divided into 2 groups: group 1, n=99, and group 2, n=96. Of those with AH, 82% had a DF ≥ 32 at presentation. Group 1 patients had a higher prevalence of SE (38% versus 25%, P=.04), type 1 HRS (30% versus 9%, P=.0003), and short-term mortality (28% versus 7%, P=.0001). In patients with AH, a MELD score ≥20 (but not a DF ≥ 32) at presentation was an independent predictor of a SE (odds ratio [OR] 2.8 [1.0–7.9], P=.04), HRS (OR 4.0, 95% confidence interval [CI] 1.0–16.6, P=0.05), and short-term mortality (OR 6.4, 95% CI 1.1–37.6, P=.03). Kaplan-Meier survival curves confirmed that that a MELD ≥ 20 but not a DF ≥ 32 was associated with a poorer survival (P = .005 and .5, respectively). In conclusion, patients with severe AH have higher prevalence of SE, HRS, and short-term mortality compared to those with cirrhosis without AH. A MELD score ≥20 at presentation is an independent predictor of these adverse events in patients with AH who have been treated with pentoxifylline.
Literature
1.
go back to reference Caly WR, Strauss E (1993) A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 18:353–358.PubMedCrossRef Caly WR, Strauss E (1993) A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 18:353–358.PubMedCrossRef
2.
go back to reference Deschenes M, Villeneuve JP (1999) Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis. Am J Gastroenterol 94:2194–2197. Deschenes M, Villeneuve JP (1999) Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis. Am J Gastroenterol 94:2194–2197.
3.
go back to reference Ginès A, Escorsell A, Ginès P, Salo J, Jiménez W, Inglada L, Navasa M, et al (1993) Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterol 105:229–236. Ginès A, Escorsell A, Ginès P, Salo J, Jiménez W, Inglada L, Navasa M, et al (1993) Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterol 105:229–236.
4.
go back to reference Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, et al (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatol 23:164–176.CrossRef Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, et al (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatol 23:164–176.CrossRef
5.
go back to reference Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, et al (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatol 36:941–948. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, et al (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatol 36:941–948.
6.
go back to reference Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, Benhamou JP, Chaput JC, Rueff B, Poynard T (1996) Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterol 110:1847–1853.CrossRef Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, Benhamou JP, Chaput JC, Rueff B, Poynard T (1996) Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterol 110:1847–1853.CrossRef
7.
go back to reference Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O (2000) Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastoenterol 119:1637–1648.CrossRef Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O (2000) Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastoenterol 119:1637–1648.CrossRef
8.
go back to reference Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr (1978) Corticosteroid therapy of alcoholic hepatitis. Gastroenterol 75:193–199. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr (1978) Corticosteroid therapy of alcoholic hepatitis. Gastroenterol 75:193–199.
9.
go back to reference Theodossi A, Eddleston AL, Williams R (1982) Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 23:75–9.PubMedCrossRef Theodossi A, Eddleston AL, Williams R (1982) Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 23:75–9.PubMedCrossRef
10.
go back to reference Caithers RL Jr, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, et al (1989) Methylprednisolone therapy in patients with severe alcoholic hepatitis: a randomized multicenter trial. Ann Intern Med 110:685–690. Caithers RL Jr, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, et al (1989) Methylprednisolone therapy in patients with severe alcoholic hepatitis: a randomized multicenter trial. Ann Intern Med 110:685–690.
11.
go back to reference Ramond MJ, Poynard T, Rueff B, Mathurin P, Theodore C, Chaput JC, et al (1992) A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Eng J Med 326:507–512.CrossRef Ramond MJ, Poynard T, Rueff B, Mathurin P, Theodore C, Chaput JC, et al (1992) A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Eng J Med 326:507–512.CrossRef
12.
go back to reference Sarper R, Tarcan YA (1983) An improved method of estimating the portal venous fraction of the hepatic blood flow from computerized radionuclide angiography. Radiology 147:559–562.PubMed Sarper R, Tarcan YA (1983) An improved method of estimating the portal venous fraction of the hepatic blood flow from computerized radionuclide angiography. Radiology 147:559–562.PubMed
13.
go back to reference Runyon B (1998) Management of adult patients with ascites caused by cirrhosis. AASLD Practice guidelines. Hepatol 27:264–272. Runyon B (1998) Management of adult patients with ascites caused by cirrhosis. AASLD Practice guidelines. Hepatol 27:264–272.
14.
go back to reference Rehberg PB (1926) Studies on kidney function. I. The rate of filtration and reabsorption in the human kidney. Biochem J 20:447–453.PubMed Rehberg PB (1926) Studies on kidney function. I. The rate of filtration and reabsorption in the human kidney. Biochem J 20:447–453.PubMed
15.
go back to reference Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Ter Borg PCJ (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatol 31:864–871.CrossRef Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Ter Borg PCJ (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatol 31:864–871.CrossRef
16.
go back to reference Baudouin SV, Grey H, Hall-Craggs M, Wells CP, Rake MO, Coakley AJ (1986) Liver scintiscanning as a screening test in the detection of alcoholic cirrhosis. Nucl Med Commun 7:71–75.PubMedCrossRef Baudouin SV, Grey H, Hall-Craggs M, Wells CP, Rake MO, Coakley AJ (1986) Liver scintiscanning as a screening test in the detection of alcoholic cirrhosis. Nucl Med Commun 7:71–75.PubMedCrossRef
17.
go back to reference Rimola A, Soto R, Bory F, Arroyo V, Piera C, Rodes J (1984) Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 4:53–58.PubMedCrossRef Rimola A, Soto R, Bory F, Arroyo V, Piera C, Rodes J (1984) Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 4:53–58.PubMedCrossRef
18.
go back to reference Bereny MR, Straus B, Cruz D (1974) In vitro and in vivo studies of cellular immunity in alcoholic cirrhosis. Am J Dig Dis 19:199–205.CrossRef Bereny MR, Straus B, Cruz D (1974) In vitro and in vivo studies of cellular immunity in alcoholic cirrhosis. Am J Dig Dis 19:199–205.CrossRef
19.
go back to reference Pol S, Durand F, Bernuau J, Colin JF, Dubois F, Hautekeete M, Rouzioux C, Degott C, Rueff B, Benhamou JP (1992) Herpesvirus infection of the respiratory tract in patients with alcoholic hepatitis. Alcohol Clin Exp Res 16:979–981.PubMedCrossRef Pol S, Durand F, Bernuau J, Colin JF, Dubois F, Hautekeete M, Rouzioux C, Degott C, Rueff B, Benhamou JP (1992) Herpesvirus infection of the respiratory tract in patients with alcoholic hepatitis. Alcohol Clin Exp Res 16:979–981.PubMedCrossRef
20.
go back to reference Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, Rimola A, Gassull MA, Arroyo V, Rodes J (1994) Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 20:1495–1501.PubMedCrossRef Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, Rimola A, Gassull MA, Arroyo V, Rodes J (1994) Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 20:1495–1501.PubMedCrossRef
21.
go back to reference Morgan TR, McClain CJ (2000) Pentoxifylline and alcoholic hepatitis [editorial]. Gastroenterology 119:1787–1790.PubMedCrossRef Morgan TR, McClain CJ (2000) Pentoxifylline and alcoholic hepatitis [editorial]. Gastroenterology 119:1787–1790.PubMedCrossRef
22.
go back to reference Mathurin P, Mendenhall CL, Carithers RL Jr, Ramond MJ, Maddrey WC, Garstide P, Rueff B, Naveau S, Chaput JC, Poynard T (2002) Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 36:480–487.PubMedCrossRef Mathurin P, Mendenhall CL, Carithers RL Jr, Ramond MJ, Maddrey WC, Garstide P, Rueff B, Naveau S, Chaput JC, Poynard T (2002) Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 36:480–487.PubMedCrossRef
23.
go back to reference Imperiale TF, McCullough AJ (1990) Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 113:299–307.PubMed Imperiale TF, McCullough AJ (1990) Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 113:299–307.PubMed
24.
go back to reference Christensen E, Gluud C (1995) Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 37:113–118.PubMedCrossRef Christensen E, Gluud C (1995) Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 37:113–118.PubMedCrossRef
25.
go back to reference Cabre E, Rodriguez-Iglesias R, Caballeria J, Quer JC, Sanchez-Lombrana JL, Pares A, Papo M, Planas R, Gassull MA on behalf of The Spanish Group for the Study of Alcoholic Hepatitis (2000) Short-and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 32:36–42.PubMedCrossRef Cabre E, Rodriguez-Iglesias R, Caballeria J, Quer JC, Sanchez-Lombrana JL, Pares A, Papo M, Planas R, Gassull MA on behalf of The Spanish Group for the Study of Alcoholic Hepatitis (2000) Short-and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 32:36–42.PubMedCrossRef
26.
go back to reference Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet M-A, et al (2004) A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 39:1390–1397.PubMedCrossRef Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet M-A, et al (2004) A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 39:1390–1397.PubMedCrossRef
27.
go back to reference Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey MR (2004) Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 40:897–903.PubMedCrossRef Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey MR (2004) Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 40:897–903.PubMedCrossRef
28.
go back to reference Srikureja W, Kyulo NL, Runyon BA, Hu KQ (2005) MELD score is a better prognostic model than Child-Turcotte-Pugh score or discriminant function score in patients with alcoholic hepatitis. J Hepatol 42:700–706.PubMedCrossRef Srikureja W, Kyulo NL, Runyon BA, Hu KQ (2005) MELD score is a better prognostic model than Child-Turcotte-Pugh score or discriminant function score in patients with alcoholic hepatitis. J Hepatol 42:700–706.PubMedCrossRef
29.
go back to reference Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, Malinchoc M, Kamath PS, Shah V (2005) MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 41:353–358.PubMedCrossRef Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, Malinchoc M, Kamath PS, Shah V (2005) MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 41:353–358.PubMedCrossRef
Metadata
Title
Prevalence of Septic Events, Type 1 Hepatorenal Syndrome, and Mortality in Severe Alcoholic Hepatitis and Utility of Discriminant Function and MELD Score in Predicting These Adverse Events
Authors
Sumita Verma
Ketan Ajudia
Michel Mendler
Allan Redeker
Publication date
01-09-2006
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2006
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9099-z

Other articles of this Issue 9/2006

Digestive Diseases and Sciences 9/2006 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.